Table 1.
Demographic and disease characteristics at randomization
| Arm 1 Bevacizumab Nab-paclitaxel DD AC |
Arms 2 and 3 No Bevacizumab Nab-paclitaxel DD AC |
Total | |
|---|---|---|---|
| Randomized | 99 | 116 | 215 |
| Ineligible or withdrew consent | 1 (1.0 %) | 3 (2.6 %) | 4 (1.9 %) |
| Analyzed | 98 | 113 | 211 |
| Age median (range) | 51.7 (22–71) | 51.3 (31–75) | 51.5 (22–75) |
| Race | |||
| White | 70 (71.4 %) | 84 (74.3 %) | 154 (73.0 %) |
| Black | 20 (20.4 %) | 18 (15.9 %) | 38 (18.0 %) |
| Asian/Pacific Islander | 5 (5.1 %) | 6 (5.3 %) | 11 (5.2 %) |
| Other/unknown | 3 (3.1 %) | 5 (4.4 %) | 8 (3.8 %) |
| IBC or Non-IBC LABC | |||
| IBC | 10 (10.2 %) | 14 (12.4 %) | 24 (11.4 %) |
| Non-IBC LABC | 88 (89.8 %) | 99 (87.6 %) | 187 (88.6 %) |
| Hormone receptor status | |||
| Positive: ER+ or PgR+ | 66 (67.3 %) | 78 (69.0 %) | 144 (68.2 %) |
| Negative: ER− and PR− (TNBC) | 32 (32.7 %) | 35 (31.0 %) | 67 (31.8 %) |
| Breast cancer stage (1 missing) | |||
| IIB | 35 (35.7 %) | 52 (46.4 %) | 87 (41.4 %) |
| IIIA | 32 (32.6 %) | 30 (26.8 %) | 62 (29.5 %) |
| IIIB | 29 (29.6 %) | 24 (21.4 %) | 53 (25.2 %) |
| IIIC | 2 (2.0 %) | 6 (5.4 %) | 8 (3.8 %) |